A step-by-step cell culture process may improve the quantity and quality of cell replacement therapies.
一逐步之胞培程，可以提高胞替代法的量及品。
Insulin administration is the current mainstay of type 1 diabetes therapy, but it requires frequent injections and monitoring to provide patients with glycemic control. As cell therapies gain traction in the clinic for different disease states, researchers aim to optimize this approach for future diabetes treatments.
施予胰素，是目前第1型糖尿病治的主要方法。不，需要繁注射及，提供患者的血糖控制。著胞法，在不同疾病的床中，得引(注)。研究人力最佳化此方法，供未糖尿病法之用。
Scientists are looking into islet transplantation as a promising alternative to insulin injections, primarily by creating islet-like cells from human pluripotent stem cell (hPSC) cultures.
科家正行研究胰移植，作胰素注射一有指望的替代方案。主要藉由，人多能胞(hPSC)培物中，生胰胞。
Differentiating stem cells into high-quality insulin-producing cells on a large scale for therapeutic manufacturing is a common bottleneck in translational research.
胞大模分化成高品之生胰素的胞，供治之造用，在移之研究中，是常的一瓶。
In a study published in Stem Cell Research & Therapy, a team of diabetes researchers led by Timothy Kieffer at the University of British Columbia investigated ways to improve scalable manufacturing and demonstrated key parameters for monitoring quality during cell therapy production.
在一由加拿大英哥比大，Timothy Kieffer的一支糖尿病研究，表於《胞研究暨法》期刊的研究中，查研究了，於胞法生期，改可展造的方法且了，胞法生程中，控品的。
Their work provides insights for the larger-scale production of hPSC-derived pancreatic cells and suggests ways to standardize the manufacturing process.
他的研究提供了，有大模生，衍生自hPSC之胰胞的洞察力。且提出了，化造程的方法。
The researchers applied a quality-by-design approach, which interrogates the experimental process as part of drug development rather than only testing the properties of the final product. They used this approach to investigate and improve insulin-producing cell manufacturing.
此些研究人用了一，程，作物的一部分，而不只是最品特性之品源於的方法。他使用了此方法，查研究及改生胰素之胞的造。
“In this instance, the process is the product as well, because what we are doing and how we are doing it could impact the quality of the cells that are being made,” explained Priye Iworima, a bioprocess engineer from Kieffer’s laboratory who spearheaded this work.
自展研究之Kieffer室的生物程工程，Priye Iworima解：「在此情下，程也是品。因，我正在做的事情及我如何做，影正在造的胞品。」
Iworima and her colleagues developed and optimized a seven-step cell manufacturing process that differentiates hPSC into insulin-producing islet-like clusters.
Iworima及其同僚最佳化了一，可hPSC分化成，生胰素之胰簇之七步的胞造程。
At each differentiation step, they characterized bioprocess parameters such as cell proliferation, glucose consumption and lactate production rates, and cell fate biomarkers.
在每一分化步中，他描了，如胞增殖、葡萄糖消耗乳酸酶生率，及胞宿命生物等，生物程。
The researchers enhanced cell yield by adjusting the cell culture process, and they revealed a gradual metabolic shift from glycolysis to oxidative phosphorylation that scientists can monitor as a quality control metric during scalable manufacturing.
藉由整胞培程，此些研究人提高了胞量。而且他揭露了一，科家能在可展造期行，作品控制衡量指之糖酵解到氧化磷酸化的逐代化。
“This paper is interesting in that it fills in a gap,” said stem 胞生物家Joe Zhou Weill Cornell Medicine, who investigates organoid-derived cell replacement therapies for diabetes and who was not involved in this study. “In terms of how you scale production or do quality control, how do you industrialize a cell therapy from the lab toward the clinic? We see very few publications like that in this field.”
未研究，自美威康奈院，行查研究衍生自器官之胞，供糖尿病作替代法的胞生物家，Joe Zhou宣：「文是引人注目的，因它填了一空白。有如何大生或行品控制，如何使胞法，室化到床？在此域中，我很少看到似上述的刊物。」
Iworima believes that her findings will also help researchers evaluate whether intermediate cell products are useful for certain subsets of patients, which could shorten and simplify the manufacturing process.
Iworima，她可能短及化造程的，也助研究人，估居的胞品，是否某些患者子群有用。
“Eventually, we will have different cell products that may be best suited to the individual, whether it is the more terminally differentiated islet-like cluster, or whether it is the pancreatic progenitor,” Iworima said.
Iworima宣：「最，我有可能是最合人的不同胞品。不管是末端分化的胰簇，是胰源祖胞。」
Previous transplant studies with diabetic rodent models suggested that progenitor cells may be adequate for mature beta cell function postimplantation. The quality control parameters highlighted along the step-by-step process in this study could facilitate future translational applications for progenitor cells and fully differentiated cells alike.
先前多以糖尿病之物模型的移植研究暗示，源祖胞或足植入後，成熟之β胞功能的需求。於此研究中，按照逐步程的品控制，一可能促源祖胞及完全分化之胞，未的移用。
If scientists can overcome in vitro manufacturing barriers such as scale and quality control limitations, cell culture methods for growing insulin-producing islet mimics may help diabetes cell replacement therapies reach patients.
倘若科家能克服，於外造的多障，如模及品控制等限制。那用於培生胰素之胰模物的胞培方法，可能有助於使糖尿病胞替代法及於患者。
“The journey of a laboratory protocol from the bench to bedside—people always talk about that. But most of the papers are about the bench,” Zhou said. “It will be good to have this knowledge out there so people do not have to reinvent the wheel. It will be very helpful.”
Zhou宣：「人是，一台到床之室治方案的程。不，此些大多是有台上的文。在那，有此知是可靠的，人就不必地重。是非常有助的。」
址：https://www.the-scientist.com/making-moves-toward-cell-therapy-for-diabetes-71659
翻：
文章定位：
